- By insider

CEO of Madrigal Pharmaceuticals Inc (MDGL) Paul A Friedman bought 4,000 shares of MDGL on 11/20/2018 at an average price of $117.88 a share. The total cost of this purchase was $471,520.

Madrigal Pharmaceuticals Inc is a company focused on the development of novel compounds for the treatment of cardiovascular-metabolic diseases and nonalcoholic steatohepatitis (NASH). Madrigal Pharmaceuticals Inc has a market cap of $1.75 billion; its shares were traded at around $113.38 . Madrigal Pharmaceuticals Inc had annual average EBITDA growth of 43.80% over the past five years.

• Warning! GuruFocus has detected 4 Warning Signs with T. Click here to check it out.

• MDGL 15-Year Financial Data

• The intrinsic value of MDGL

• Peter Lynch Chart of MDGL

CEO Recent Trades:

• CEO Paul A Friedman bought 4,000 shares of MDGL stock on 11/20/2018 at the average price of $117.88. The price of the stock has decreased by 3.82% since.

• CEO Paul A Friedman bought 4,000 shares of MDGL stock on 11/19/2018 at the average price of $124. The price of the stock has decreased by 8.56% since.

Directors and Officers Recent Trades:

• Director, 10% Owner Fred B Craves bought 2,000 shares of MDGL stock on 11/19/2018 at the average price of $124.69. The price of the stock has decreased by 9.07% since.

For the complete insider trading history of MDGL, click here

.This article first appeared on GuruFocus.

• Warning! GuruFocus has detected 4 Warning Signs with T. Click here to check it out.

• MDGL 15-Year Financial Data

• The intrinsic value of MDGL

• Peter Lynch Chart of MDGL